The U.S. Food and Drug Administration has approved two new medications for Crohn’s disease, following the results of successful multisite clinical trials conducted in part at the Icahn School of Medicine at Mount Sinai. The therapies, interleukin-23 inhibitors mirikizumab and guselkumab, fill an important gap in Crohn’s disease treatment.